Posters

Subconjunctival anti-VEGF injection; clinical outcomes in 16 cases of corneal neovascularization after infectious corneal ulcer

Poster Details

First Author: R.Setyowati INDONESIA

Co Author(s):    S. Pawiroranu                    

Abstract Details

Purpose:

To evaluate the clinical outcomes and its antiangiogenic effect of the subconjunctival anti-VEGF injection on corneal neovascularization after infectious corneal ulcer.

Setting:

This study included 16 patients who developed corneal neovascularization after infectious corneal ulcer from March-August 2019. This was interventional case series, one groups pretest-posttest design.

Methods:

Patients received anti-VEGF (Bevacizumab) solution subconjunctivally in a single dose (25 mg/ml). The primary outcome were the number of corneal segments affected by corneal neovascularization using corneal pattern attached to the digital photograph of the cornea. Other evaluation including LogMAR Visual Acuity (LogMAR VA) and the incidence of complications related to the treatment. The minimum follow-up period was three months.

Results:

The percentage reduction of the affected segments was 19,24% (p<0,01; p = 0,000) after 1 month, 22,16% (p < 0,01; p = 0,000) after 2 months and 35,35% (p<0,01; p = 0,000) at the end of evaluation. There were significant difference of visual acuity after 1 month and 3 months (p<0,05 ; p=0,015 and p=0,022; ). There were no complications reported.

Conclusions:

The use of the subconjunctival anti-VEGF injection on corneal neovascularization after infectious corneal ulcer seems to be an effective and safe method.

Financial Disclosure:

None